中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

202 records (took 0.024 seconds)

    PD-1-based vaccines against coronavirus infection
    44.
    发明授权
    PD-1-based vaccines against coronavirus infection 有权

    公开(公告)号：US12018063B2

    公开(公告)日：2024-06-25

    申请号：US17186822

    申请日：2021-02-26

    Applicant: Versitech Limited

    Inventor： Zhiwei Chen ,  Kwok Yung Yuen ,  Honglin Chen ,  Yik Chun Wong ,  Li Liu

    IPC: C07K14/705 ,  A61K39/12 ,  A61P31/14 ,  C07K14/165

    CPC classification number: C07K14/70521 ,  C07K14/165 ,  C07K2319/30

    Abstract: Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.

    COMPOSITIONS FOR CORONAVIRUS DETECTION AND METHODS OF MAKING AND USING THEROF
    47.
    发明公开
    COMPOSITIONS FOR CORONAVIRUS DETECTION AND METHODS OF MAKING AND USING THEROF 审中-公开

    公开(公告)号：US20240124947A1

    公开(公告)日：2024-04-18

    申请号：US18473956

    申请日：2023-09-25

    Applicant: Versitech Limited ,  Centre for Virology, Vaccinology and Therapeutics Limited ,  THE HOSPITAL AUTHORITY

    Inventor： Kelvin Kai-Wang To ,  Siddharth Sridhar ,  Kwok-Yung Yuen ,  Chik Yan Yip

    IPC: C12Q1/70

    CPC classification number: C12Q1/701 ,  C12Q2600/16

    Abstract: Sequences for detection of SARS-CoV-2 are provided and include example, SEQ ID NOs:4-8. The sequences are useful for amplifying the SARS-CoV-2 nsp8 gene in a sample, using Reverse Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) and it is preferably used in combination with a Cas enzyme/sgRNA pair and a reporter nucleic acid.
    The disclosed sequences can be use in methods of detecting SARS-CoV-2 nucleic acids in a sample. Generally, the specific gene sequence of SARS-CoV-2 RNA, herein nsp8, is amplified using RT-LAMP. The RT-LAMP products are scanned by the Cas12a-gRNA ribonucleoprotein (RNP) complex. The RNP binds to the specific complementary to gRNA, activating the transcleavage activity of Cas12a. The active Cas12a system cleaves a short ssDNA reporter that is labeled preferably, with a fluorophore and a quencher on either end. Cleavage of the reporter separates the quencher from the fluorophore, and fluorescence that is detectable with the naked eye is generated.

    COMPOSITIONS IMMUNOGENIC AGAINST INFLUENZA AND SARS CORONAVIRUS 2, METHODS OF MAKING AND USING THEREOF
    49.
    发明公开
    COMPOSITIONS IMMUNOGENIC AGAINST INFLUENZA AND SARS CORONAVIRUS 2, METHODS OF MAKING AND USING THEREOF 审中-公开

    公开(公告)号：US20240050558A1

    公开(公告)日：2024-02-15

    申请号：US18267931

    申请日：2021-12-10

    Applicant: Versitech Limited

    Inventor： Honglin Chen ,  Pui Wang ,  Zhiwei Chen ,  Kwok-Yung Yuen

    IPC: A61K39/215 ,  A61P31/14 ,  C07K14/165 ,  A61K9/00

    CPC classification number: A61K39/215 ,  A61P31/14 ,  C07K14/165 ,  A61K9/0043 ,  A61K2039/5254

    Abstract: Live attenuated viruses for protection against the novel coronavirus Sars-CoV-2 are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza A or B virus (LAIVA/B), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-A/B-Sars-CoV-2-CoV2Ag. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33° C. Compositions including the chimeric virus also provided as a co-composition with a LAIVA/B. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. The co-compositions can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2 and influenza A and/or B.

    Bone model, modelling process and system therefor
    50.
    发明授权
    Bone model, modelling process and system therefor 有权

    公开(公告)号：US11864978B2

    公开(公告)日：2024-01-09

    申请号：US16645424

    申请日：2017-09-07

    Applicant: VERSITECH LIMITED

    Inventor： Sloan Austin Kulper ,  Hing Wan Alfonso Ngan ,  Xinshuo Christian Fang ,  Margaret Guo ,  Weijia William Lu ,  Ka Li Frankie Leung

    IPC: A61F2/30 ,  G16H10/60 ,  G16H50/70 ,  G16H30/40 ,  G06F30/20

    CPC classification number: A61F2/30942 ,  G06F30/20 ,  G16H10/60 ,  G16H30/40 ,  G16H50/70 ,  A61F2002/30948 ,  A61F2002/30952

    Abstract: A computer-implemented bone-implant system evaluation method for application of mesh-free analysis of a bone-implant system for evaluation of performance of a bone-implant system for an implant implanted within the bone structure at an anatomical site, said method comprising (i) receiving a set of bone structure data set, wherein set of bone structure data includes data indicative of the bone structure at an anatomical site; (ii) inputting an implant data set and inputting the position of the implant data set, wherein the implant is selected based upon the biomechanical requirements for the anatomical site and the position and of the implant data set is indicative of the position of the implant with respect to the anatomical site, wherein implant data set includes data representative of the geometry and materials properties of the implant; (iii) creating a bone-implant model, wherein said bone implant-model includes a mesh-free model of trabecular bone at the anatomical site wherein the bone-implant model is formed from the bone structure data set from step (i) and the implant data set from step (ii), and wherein the mesh-free model of trabecular bone is indicative of the trabecular bone structure of the bone structure at the anatomical site; and (iv) determining a biomechanical result based upon computer simulated loading of the bone-implant system based upon mesh-free analysis of the bone-implant model, wherein the biomechanical result includes data based on the displacement of the implant relative to the bone of bone-implant model.

Patent Agency Ranking